Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 10, 2005 - Issue 2
Submit an article Journal homepage
150
Views
34
CrossRef citations to date
0
Altmetric
Review

Emerging drugs in Tourette syndrome

Yavuz S SilayBaylor College of Medicine Parkinson’s disease Center and Movement Disorders Clinic, Department of Neurology, 6550 Fannin Suite 1801, Houston, TX 77030 USATel: +1 713 798 5998; Fax: +1 713 798 6808;E-mail: [email protected]
&
Joseph JankovicBaylor College of Medicine Parkinson’s disease Center and Movement Disorders Clinic, Department of Neurology, 6550 Fannin Suite 1801, Houston, TX 77030 USATel: +1 713 798 5998; Fax: +1 713 798 6808;E-mail: [email protected]
Pages 365-380 | Published online: 10 May 2005

Bibliography

  • JANKOVIC J: Tourettewsw 's syndrome. N Engl. J. Med. (2001) 345:1184–1192.
  • MASON A, BANERJEE S, EAPEN V, ZEITLIN H, ROBERTSON MM: The prevalence of Tourette syndrome in a mainstream school population. Dev. Med. Child. Neurol (1998) 40:292–296.
  • KURLAN R, MCDERMOTT MP, DEELEY C et al.: Prevalence of tics in schoolchildren and association with placement in special education. Neurology (2001) 57(8):1383–1388.
  • PAPPERT EJ, GOETZ CG, LOUIS ED, BLASUCCI L, LEURGANS S: Objective assessments of longitudinal outcome in Gilles de la Tourette's syndrome. Neurology (2003) 61(7):936–940.
  • •A valuable attempt to establish objective assessments of longitudinal outcome in TS.
  • BURD L, KERBESHIAN PJ, BARTH A, KLUG MG, AVERY PK, BENZ B: Long-term follow-up of an epidemiologically defined cohort of patients with Tourette syndrome. J. Child. Neurol (2001) 16(6):431–437.
  • LECKMAN JF: Tourette 's syndrome. Lancet (2002) 16(360):1577–1586.
  • SINGER HS: Neurobiology of Tourette syndrome. Neurol Clin. (1997) 15:357–379.
  • ROBERTSON MM, STERN JS: Tic disorders: new developments in Tourette syndrome and related disorders. Curr. Opin. NeuroL (1998) 11(4):373–380.
  • SALLEE FR, KURLAN R, GOETZ CG et al.: Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study./ Am. Acad. Child Adolesc. Psychiatry (2000) 39(3):292–299.
  • GOODNICK PJ, JERRY JM: Aripiprazole: profile on efficacy and safety. Expert Opin. Pharmacother. (2002) 3:1773–1781.
  • PIACENTINI J, CHANG S: Behavioural treatments for Tourette syndrome and tic disorders: state of the art. Adv. NeuroL (2001) 85:319–331.
  • COHEN DJ, JANKOVIC J, GOETZ CG: Advances in Neurology volume 85: Tourette Syndrome. Lippincott Williams and Wilkins, Philadelphia, US (2001):31–42.
  • ROBERTSON MM, STERN JS: Gilles de la Tourette syndrome: symptomatic treatment based on evidence. Eur. Child Adolesc. Psychiatry (2000) 9(1):160–175.
  • JIMENEZ-JIMENEZ FJ, GARCIA RUIZ PJ: Pharmacological options for the treatment of Tourette's disorder. Drugs (2001) 61:2207–2220.
  • ZAMETKIN AJ, ERNST M: Problems in the management of attention-deficit-hyperactivity disorder. N Engl. J. Med. (1999) 340:40–46.
  • ELIA J, AMBROSINI PJ, RAPOPORT JL: Treatment of attention-deficit-hyperactivity disorder. N Engl. J. Med. (1999) 340:780–788.
  • RIDDLE MA, CARLSON J: Clinical psychopharmacology for Tourette syndrome and associated disorders. In: Advances in Neurology, volume 85: Tourette Syndrome. DJ Cohen, J Jankovic, CG Goetz (Eds), Lippincott Williams and Wilkins, Philadelphia, US (2001):343–354.
  • GADOW KD, SVERD J, SPRAFKIN J, NOLAN EE, GROSSMAN S: Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch. Gen. Psychiatry (1999) 56(4):330–336.
  • LAW SF, SCHACHAR RJ: Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? J. Am. Acad. Child Adolesc. Psychiatry (1999) 38(8):944–951.
  • KURLAN R: Methylphenidate to treat ADHD is not contraindicated in children with tics. Mov. Disord. (2002) 17:5–6.
  • THE TOURETTE 'S SYNDROME STUDY GROUP: Treatment of ADHD in 375 Expert Opin. Emerging Drugs (2005) 10(2) children with tics: a randomized controlled trial. Neurology (2002) 58:527–536.
  • •A randomised controlled trial of the treatment of ADHD in children with tics.
  • GAINETDINOV RR, WETSEL WC, JONES SR et al.: Role of serotonin in the paradoxical calming of psychostimulants in hyperactivity. Science (1999) 283:397–401.
  • BOBB AJ, CASTELLANOS FX, ADDINGTON AM, RAPOPORT JL: Molecular genetic studies of ADHD: 1991 to 2004. Am. J. Med. Genet. (2005) 132:109–125.
  • •A comprehensive overview of molecular genetic studies of ADHD.
  • LECKMAN JF, HARDIN MT, RIDDLE MA, STEVENSON J, ORT SI, COHEN DJ: Clonicline treatment of Tourette's syndrome. Arch. Gen. Psychiatry (1991) 48:324–328.
  • SCAHILL L, CHAPPELL PB, KIM YS et al.: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am. J. Psychiatry (2001) 158(7):1067–1074.
  • BALLDIN J, BERGGREN U, ERIKSSON E, LINDSTEDT G, SUNDKLER k Guanfacine as an alpha-2-agonist inducer of growth hormone secretion-a comparison with clonidine. Psychoneuroendocrinology (1993) 18(1):45–55.
  • JANKOVIC J: Deprenyl in attention deficit associated with Tourette's syndrome. Arch. Neurol (1993) 50(3):286–288.
  • FEIGIN A. KURLAN R, MCDERMOTT MP et al.: A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology (1996) 46(4):965–968.
  • OLFSON M: New options in the pharmacological management of attention-deficit/hyperactivity disorder. Am. J. Manag. Care (2004) 10(4 Suppl.):S117–S124.
  • KELSEY DK, SUMNER CR, CASAT CD et al.: Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics (2004) 114(1):1–8.
  • ••A well-designed double-blind, placebo-controlled trial demonstrating the efficacy of atomoxetine treatment for children with ADHD.
  • BUITELAAR JK, DANCKAERTS M, GILLBERG C et al.: Stomoxetine International Study Group: a prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur. Child Adolesc. Psychiatry (2004) 13(4):249–257.
  • GRADOS M, SCAHILL L, RIDDLE MA: Pharmacotherapy in children and adolescents with obsessive-compulsive disorder. Child Adolesc. Psychiatr. Clin. N Am. (1999) 8:617–634.
  • FLAMENT MF, BISSERBE J-C: Pharmacologic treatment of obsessive-compulsive disorder: comparative studies. Clin. Psychiatry (1997) 58(Suppl. 12):18–22.
  • GELLER DA, BIEDERMAN J, STEWART SE et al.: Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am. J. Psychiatry (2003) 160(1 0:1919–1928.
  • •A valuable metaanalysis of pharmacotherapy trials in paediatric OCD.
  • WHITTINGTON CJ, KENDALL T, FONAGY P, COTTRELL D, COTGROVE A, BODDINGTEN E: Selective serotonin re-uptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet (2004) 24:363(9418):1341–1345.
  • •An interesting review of selective serotonin reuptake inhibitors in childhood depression.
  • TEMEL Y, VISSSER-VAN DE WALLE V: Surgery in Tourette syndrome. Mov. Disord. (2004) 19:3–14.
  • •A nice overview of current surgical options in TS.
  • VAN DE WALLE V VAN DER LINDEN C, GROENEGEN HJ, CAEMAERT J: Stereotactic treatment of Gilles de la Tourette syndrome by high frequency stimulation of thalamus. Lancet (1999) 353:724.
  • NUTTIN B, COSYNS P, DEMEULEMEESTER H, GYBELS J, MEYERSON B: Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder. Lancet (1999) 354: 1526.
  • SEIGNOT MJN: A case of tic of Gilles dela Tourette cured by R 1625. Ann. Med. PsychoL (1961) 119:578–579.
  • CAPRINI G, MELOTTI V: Un grave sindrome ticcosa guarita con haloperidol. Riv Sper Freniatr Med. Leg Alienazioni Ment (1961) 85:191–196.
  • ABUZZAHAB FE Sr, ANDERSON FO: Gilles de la Tourette's syndrome; international registry. Minn. Med. (1973) 56(6):492–496.
  • SHAPIRO AK, SHAPIRO E, WAYNE H: Treatment of Tourette's syndrome with haloperidol, review of 34 cases. Arch. Gen. Psychiatry (1973) 28(1):92–97.
  • CONNEL PH, CORBET JA, HORN DJ, MATHEW AM: Drug treatment of adolescent tiqueurs. A double-blind trial of diazepam and haloperidol. Br. J. Psychiatry (1967) 113(497):375–381.
  • SHAPIRO E, SHAPIRO AK, FULOP G et al.: Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch. Gen. Psychiatry (1989) 46:722–730.
  • SHAPIRO AK, SHAPIRO E, EISENKRAFT GJ: Treatment of Gilles de la Tourette's syndrome with clonidine and neuroleptics. Arch. Gen. Psychiatry (1983) 40(11):1235–1240.
  • ROSS MS, MOLDOFSKY H: A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. Am. J. Psychiatry (1978) 135(5):585–587.
  • SINGER HS, GAMMON K, QUASKEY S: Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr. Neurosci. (1985) 12(2):71–74.
  • SALLEE FR, NESBITT L, JACKSON C, SINE L, SETHURAMAN G: Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am. J. Psychiatry (1997) 154(8):1057–1062.
  • GOETZ CG, TANNER CM, KLAWANS HL: Fluphenazine and multifocal tic disorders. Arch. Neurol (1984) 41(3):271–272.
  • DEBRAY P, MESSERSCHMITT P, LONCHAMP D, HERBAULT M: Eutilization du pimozide en pedopsychiatrie. Nouv. Presse Med. (1972) 1(43):2917–2918.
  • MEJIA NI, JANKOVIC J: Tardive dyskinesia and withdrawal emergent syndrome in children. (2005) (in press).
  • PAOLUCCI S, BUTTINELLI C, FIUME S, GIANT S, LENZI GL: Treatment of Gilles de la Tourette syndrome with depot neuroleptics. Acta Neurol (1984) 6(3):222–224.
  • CLARKE DJ, FORD R: Treatment of refractory Tourette syndrome with haloperidol decanoate. Acta Psychiatr. Scand. (1988) 77:495–496.
  • SHAPIRO AK, SHAPIRO E: Controlled study of pimozide versus placebo in Tourette's syndrome. J. Am. Acad. Child Psychiatry (1984) 23: 161–173.
  • REGEUR L, PAKKENBERG B, FOG R, PAKKENBERG H: Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette's syndrome. J. Neurol Neurosurg. Psychiatry (1986) 49(7):791–795.
  • SALLEE FR, DOUGHERTY D, SETHURAIVIAN G, VRINDAVANAM G: Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome. Biol. Psychiatry (1996) 40(10):1044–1050.
  • FULOP G, PHILLIPS RA, SHAPIRO AK, GOMES JA, SHAPIRO E, NORDLIE JW: ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am. J. Psychiatry (1987) 144(5):673–675.
  • SHAPIRO AK, SHAPIRO E, FULOP G: Pimozide treatment of tic and Tourette disorders. Pediatrics (1987) 79(6):1032–1039.
  • GLASSMAN AH, BIGGER JT Jr : Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry (2001) 158(10:1774–1782.
  • ROBERTSON MM: Tourette syndrome, associated conditions and the complexities of treatment. Brain (2000) 123(3):425–462.
  • •A nice and very detailed summary of clinical phenomenology and treatment of TS.
  • KOMPOLITI K, GOETZ CG: Hyperkinetic movement disorders misdiagnosed as tics in Gilles de la Tourette syndrome. Mov. Disord. (1998) 13(3):477–480.
  • BORISON RL, ANG L, HAMILTON WJ, DIAMOND BI, DAVIS JM: Treatment approaches in Gilles de la Tourette syndrome. Brain Res. Bull. (1983) 11(2):205–208.
  • JANKOVIC J, ROHAIDY H: Motor, behavioural and pharmacologic findings in Tourette's syndrome. Can. j Neurol. Sci. (1987) 14(3):541–546.
  • SILAY YS, VUONG KD, JANKOVIC J: The efficacy and safety of fluphenazine in patients with tourette syndrome. Neurology (2004) 62(5):506.
  • •The longest follow-up of TS patients treated with fluphenazine.
  • BRUUN RD, BUDMAN CL: Risperidone as a treatment for Tourette's syndrome. J. Clin. Psychiatry (1996) 57(1):29–31.
  • JANKOVIC J, BEACH J: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology (1997) 48:358–362.
  • QUITKIN F, RIFKIN A. GOCHFELD L, KLEIN DF: Tardive dyskinesia: are first signs reversible? Am. J. Psychiatry (1977) 134(1):84–87.
  • KUMRA S, JACOBSEN LK, LENANE M et al.: Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J. Am. Acad. Child Adolesc. Psychiatry (1988) 37(4):377–385.
  • LEYSEN JE, JANSSEN PM, GOMMEREN W, WYNANTS J, PAUWELS PJ, JANSSEN Pk In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. MoL Pharmacol (1992) 41(3):494–508.
  • STAMENKOVIC M, AUSCHAUER H, KASPER S: Risperidone for Tourette's syndrome. Lancet (1994) 344(8936):1577–1578.
  • VAN DER LINDEN C, BRUGGEMAN R, VAN WOERKOM TCA: Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome; an open pilot dose-titration study with risperidone. Mov. Disord. (1994) 9:687–688.
  • SHULMAN LM, SINGER C, WEINER WJ: Risperidone in Gilles de la Tourette syndrome. Neurology (1995) 45(7):1419.
  • GIAKAS WJ: Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder. Am. J. Psychiatry (1995) 152(7):1097–1098.
  • LOMBROSO PJ, SCAHILL L, KING RA et al.: Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J. Am. Acad. Child Adolesc. Psychiatry (1995) 34(9):1147–1152.
  • BRUGGEMAN R, VAN DER LINDEN C, BUITELAAR JK, GERICKE GS, HAWKRIDGE SM, TEMLETT JA: Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J. Clin. Psychiatry (2001) 62(1):50–56.
  • •• A comparative double-blind, parallel-group study of risperidone and pimozide in TS.
  • GAFFNEY GR, PERRY PJ, LUND BC, BEVER-STILLE KA, AMDT S, KUPERMAN S: Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41(3):330–336.
  • GILLBERT DL, BATTERSON JR, SETHURAMAN G, SALLEE FR: Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J. Am. Acad. Child Adolesc. Psychiatry (2004) 43(2):206–214.
  • ••A randomised, double-blind, crossover trialof risperidone versus pimozide.
  • ROBERTSON MM, SCULL DA, EAPEN V et al.: Risperidone in the treatment of Tourette syndrome: a retrospective case note study. Psychopharmacol (1996) 10:317–320.
  • DION Y, ANNABLE L, SANDOR P, CHOUNIARD G: Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial. J. Clin. Psychopharmacol (2002) 22(1):31–39.
  • ••A double-blind, placebo-controlled studyof risperidone in TS.
  • GIANFRANCESCO FD, GROGG AL, MAHMOUD RA, WANG RH, NASRALLAH HA: Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on Type 2 diabetes: findings from a large health plan database. J. Clin. Psychiatry (2002) 63(10):920–930.
  • STAHL SM, SHAYEGAN DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J. Clin. Psychiatry (2003) 64(19):6–12.
  • JACOBSEN FM: Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J. Clin. Psychiatry (1995) 56(9):423–429.
  • STEIN DJ, BOUWER C, HAWKRIDGE S, EMSLEY RA Risperidone augmentation of serotonin re-uptake inhibitors in obsessive-compulsive and related disorders. J. Clin. Psychiatry (1997) 58(3):119–122.
  • SCAHILL L, LECKMAN JF, SCHULTZ RT, KATSOVICH L, PETERSON BS: A placebo-controlled trial of risperidone in Tourette syndrome. Neurology (2003) 60(7):1130–1135.
  • •A placebo-controlled trial of risperidone in TS.
  • SANDOR P, STEPHENS RJ: Risperidone treatment of aggressive behavior in children with Tourette syndrome. J. Clin. PsychopharmacoL (2000) 20(6):710–712.
  • YVONNEAU M, BEZARD P: Apropos of a case of Gilles de la Tourette's disease blocked by sulpiride. Psycho-biological study. Encepha/e (1970) 59:439–459.
  • ROBERTSON MM, SCHNIEDEN LEES AJ: Management of Gilles de la Tourette syndrome using sulpiride. Clin. NeuropharmacoL (1990) 13:229–235.
  • GEORGE MS, TRIMBLE MR, ROBERTSON MM: Fluvoxamine and sulpiride in comorbid obsessive-compulsive disorder and Gilles de la Tourette syndrome. Hum. PsychopharmacoL (1993) 8:327–334.
  • LIPCSEY A: Gilles de la Tourette's disease. Sem. Hop. (1983) 59:695–696.
  • KLEPEL H, GEBELT H, KOCH RD, TZENOW H: Treatment of extrapyramidal hyperkineses in childhood with tiapride. Psychiatr. Neurol. Med. Psychol. (1988) 40(9):516–522.
  • EGGER C, ROTANBERGER A, BERGHAUS U: Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur. Arch. Psychiatry NeuroL Sci. (1988) 237(4):223–239.
  • NAKRA BR, BOND AJ, LADER MH: Comparative psychotropic effects of metoclopramide and prochlorperazine in normal subjects./ Clin. PharmacoL (1975) 15(5-6):449–454.
  • DESAI AB, DOONGAJI DR, SATOSKAR RS: Metoclopramide in Gilles de la Tourette's syndrome. J. Postgrad. Med. (1983) 29(3):181–183.
  • SMIRNOV A: Use of metoclopramide (cerucal) in Tourette syndrome. Zh. NevropatoL Psikhiatr. (1989) 89:105–108.
  • YE HC, XIE XL, YOU Y: Effects of metoclopramide on intelligence and memory in patients with Tourette syndrome. Hunan Yi Ke Da Xue Xue Bao (2003) 28(3):301–303.
  • ACOSTA MT, CASTELLANOS FX: Use of the 'inverse neuroleptic' metoclopramide in Tourette syndrome: an open case series. J. Child Adolesc. PsychopharmacoL (2004) 14(1):123–128.
  • MILLER LG, JANKOVIC J: Metoclopramide-induced movement disorders. Arch. Int. Med. (1989) 149:2386–2392.
  • PUTNAM PE, ORENSTEIN SR, WESSEL HB, STOWE RM: Tardive dyskinesia associated with use of metoclopramide in a child. J. Pediatr. (1992) 121:983–985.
  • MEJIA NI, JANKOVIC J: Metoclopramide-induced tardive dyskinesia in an infant. Mov. Disord. (2005) 20:86–89.
  • TRILLET M, MOREAU T, DALERY J, DE VILLARD R, AIMARD G: Treatment of Gilles de la Tourette's disease with amisulpiride. Presse Med. (1990) 19: 175.
  • FOUNTOULAKIS KN, IACOVIDES A, KAPRINIS GS: Successful treatment of Tourette's disorder with amisulpride. Ann. Pharmacother. (2004) 38(5):901.
  • BUITELAAR JK, VAN DER GAAG RJ, SWAAB-BARNEVELD H, KUIPER M: Prediction of clinical response to methylphenidate in children with attention-deficit hyperactivity disorder./ Am. Acad. Child Adolesc. Psychiatry (1995) 34(8):1025–1032.
  • SANDOR P, SINGAL S, ANGUS C: Remoxipride versus haloperidol treatment of Tourette's syndrome. Mov. Disord. (1996) 11(1):248.
  • POLITES DJ, KRUGER D, STEVENSON I: Sequential treatments in a case of Gilles de la Tourette's syndrome. Br. J. Med. Psychol. (1965) 38:43–52.
  • FERNANDO SJ: Gilles de la Tourette's syndrome. A report on four cases and a review of published case reports. Br. J. Psychiatry (1967) 113(499):607–617.
  • PRABHAKARAN N: A case of Gilles de la Tourette's syndrome with some observations on aetiology and treatment. Br. J. Psychiatry (1970) 116(534):539–541.
  • LECHIN F, VAN DER DIJS B, GOMEZ F, ACOSTA E, AROCHA L: On the use of clonidine and thioproperazine in a woman with Gilles de la Tourette's disease. Biol. Psychiatry (1982) 17:103–108.
  • SCHMIDER J, HOFF P: Clozapine in Tourette's syndrome. J. Clin. PsychopharmacoL (1998) 18(1):88–89.
  • SANDYK R: Naltrexone suppresses abnormal sexual behavior in Tourette's syndrome. Int. J. Neurosci. (1988) 43(1-2):107–110.
  • BUDMAN CL, GAYER A, LESSER M, SHI Q, BRUUN RD: An open-label study of the treatment efficacy of olanzapine for Tourette's disorder. J. Clin. Psychiatry (2001) 62(4):290–294.
  • BHADRINATH BR: Olanzapine in Tourette syndrome. Br. J. Psychiatry (1998) 172:366.
  • KARAM-HAGE M, GHAZIUDDIN N: Olanzapine in Tourette's Disorder./ Am. Acad. Child Adolesc. Psychiatry (2000) 39(2):139.
  • BENGI SEMERCI Z: Olanzapine in Tourette's syndrome. Br. J Psychiatry (1998) 172:366.
  • LUCAS TARACENA MT, MONTANES RADA F: Olanzapine in Tourette's syndrome: a report of three cases. Actas Esp. Psiquiatr. (2002) 30(2):129–132.
  • STAMENKOVIC M, SCHINDLERSD, AUSCHAUER HN et al.: Effective open-label treatment of tourette's disorder with olanzapine. Int. Clin. PsychopharmacoL (2000) 15(1):23–28.
  • STEPHENS RJ, BASSEL C, SANDOR P: Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome - a pilot study. J. Child Adolesc. Psychopharmacol. (2004) 14(2):255–266.
  • ONOFRJ M, PACI C, D'ANDREAMATTE0 G, TOMA L: Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind crossover study versus low-dose pimozide. NeuroL (2000) 247(0:443–446.
  • ••A double-blind crossover study ofolanzapine versus low-dose pimozide in severe TS.
  • SALLEE FR, GILBERT DL, VINKS AA, MICELI JJ, ROBARGE L, WILNER K: Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission. J. Am. Acad. Child Adolesc. Psychiatry (2003) 42(8):902–907.
  • KECK PE JR, MCELROY SL, ARNOLD LM: Ziprasidone: a new atypical antipsychotic. Expert Opin. Pharmacother. (2001) 2(6):1033–1042.
  • MEISEL A, WINTER C, ZCHENDERLEIN R, ARNOLD G: Tourette syndrome: efficient treatment with ziprasidone and normalization of body weight in a patient with excessive weight gain under tiapride. Mov. Disord. (2004) 19(8):991–992.
  • PARRAGA HC, WOODWARD RL: Quetiapine for Tourette's syndrome. J. Am. Acad. Child Adolesc. Psychiatry (2001) 40(4):389–391.
  • COHEN LS: Quetiapine in treatment-resistant obsessive-compulsive disorder. J. Am. Acad. Child Adolesc. Psychiatry (2003) 42(6):623–624.
  • MATUR Z, UCOK A: Quetiapine treatment in a patient with Tourette's syndrome, obsessive-compulsive disorder and drug-induced mania. Isr. J. Psychiatry Relat. Sci. (2003) 40(2):150–152.
  • MUKADDES NM, ABALI 0: Quetiapine treatment of children and adolescents with Tourette's disorder. J. Child Adolesc. Psychopharmacol (2003) 13(3):295–299.
  • KASTRUP A, SCHLOTTER W, PLEWNIA C, BARTELS M: Treatment of tics in Tourette's syndrome with aripiprazole. J. Clin. Psychopharmacol (2005) 25(1):94–96.
  • HUNTER CB, VUONG K, MEJIA N, JANKOVIC J: Tetrabenazine, a monoamine depleter, effective in the treatment of Tourette syndrome. Mov. Disord. (2004) 19\(Suppl. 9):S437.
  • TIZABI Y, RUSSEL LT, JOHNSON M, DARMANI NA: Nicotine attenuates DOT-induced head-twitch response in mice: implications for Tourette syndrome. Prog. Neuropsychopharmacol Biol. Psychiatry (2001) 25(7):1445–1457.
  • HAYSLETT RL, TIZABI Y: Effects of donepezil on DOT-induced head twitch response in mice: implications for Tourette syndrome. Pharmacol Biochem. Behav. (2003) 76(3-4):409–415.
  • SILVER AA, SHYTLE RD, SHEEHAN KH, SHEEHAN DV, RAMOS A, SANBERG PR: Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder. J. Am. Acad. Child. Adolesc. Psychiatry (2001) 40(9):1103–1110.
  • HOWSON AL, BATTH S, ILIVITSKY V: Clinical and attentional effects of acute nicotine treatment in Tourette's syndrome. Eur. Psychiatry (2004) 19(2):102–112.
  • LEVIN ED, LIPPIELLO P: Mutually potentiating effects of mecamylamine and haloperidol in producing catalepsy in rats. Drug Dev. Res. (1999) 47:90–96.
  • MULLER-VAHL KR, SCHNEIDER U, KOBLENZ A et al.: Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry (2002) 35(2):57–61.
  • MULLER-VAHL KR, SCHNEIDER U, PREVEDEL H et al.: Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J. Clin. Psychiatry (2003) 64(4):459–465.
  • GADZICKI D, MULLER-VAHL KR, HELLER D et al.: Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene. Am. J. Med. Genet. (2004) 15(1):97–103.
  • AWAAD Y: Tics in Tourette syndrome: new treatment options. J. Child Neurol. (1999) 14(5):316–319.
  • SINGER HS, WENDLANDT J, KRIEGER M, GIULIANO J: Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology (2001) 56(5):599–604.
  • ••A double-blind, placebo-controlledcrossover trial of badofen treatment in TS.
  • JANKOVIC J: Botulinum toxin in the treatment of dystonic tics. Mov. Disord. (1994) 9:347.
  • Therapy with Botulinum Toxin. Jankovic J, Hallett M (Eds), Marcel Dekker, New York, NY, US (1994):1–608.
  • MARRAS C, ANDREWS D, SIME E, LANG AE: Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology (2001) 56:605–610.
  • ••A randomised, double-blind, controlledclinical trial of botulinum toxin for simple motor tics.
  • KWAK C, DAT VUONG K, JANKOVIC J: Premonitory sensory phenomenon in Tourette's syndrome. Mov. Disord. (2003) 18:1530–1533.
  • JANKOVIC J: Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatry (2004) 75(7):951–957.
  • GOETZ CG, TANNER CM, WILSON RS, CARROLL VS, COMO PG, SHANNON KM. Clonidine and Gilles de la Tourette's syndrome: double-blind study using objective rating methods. Ann. Neurol. (1987)21:307-310.
  • CUMMINGS DD, SINGER HS, KRIEGER M, MILLER TL, MAHONE EM: Neuropsychiatric effects of guanfacine in children with mild tourette syndrome: a pilot study. Clin. Neuropharmacol (2002) 25(6):325–332.
  • GILLBERT DL, SETHURAIVIAN G, SINE L, PETERS S, SALLE FR: Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology (2000) 54(6):1310–1315.
  • ••A randomised, double-blind, crossover trialof pergolide in TS.
  • GILLBERT DL, DURE L, SETHURAMAN G, RAAB D, LANE J, SALLEE FR: Tic reduction with pergolide in a randomized controlled trial in children. Neurology (2003) 60(4):606–611.
  • •A randomised, controlled trial demonstrating tic reduction in children with pergolide.
  • DE CARVALHO AGUIAR P, FAZZARI M, JANKOVIC J, OZELIUS LJ: Examination of the SGCE gene in Tourette syndrome patients with obsessive-compulsive disorder. Mov. Disord. (2004) 19(10):1237–1238.
  • HONG JJ, LOISELLE CR, YOON DY, LEE O, BECKER KG, SINGER HS: Microarray analysis in Tourette syndrome postmortem putamen. J. Neurol Sci. (2004) 225(1-2):57–64.
  • •Microarray analysis in TS postmortem putamen.
  • GONCE M, BARBEAU A: Seven cases of Gilles de la tourette's syndrome: partial relief with clonazepam: a pilot study. Can. J. Neurol. Sci. (1977) 4(4):279–283.
  • KAIM B: A case of Gilles de la Tourette's syndrome treated with clonazepam. Brain. Res. Bull. (1983) 11(2):213–214.
  • TRUONG DD, BRESSMAN S, SHALE H, FAHN S: Clonazepam, haloperidol, and clonidine in tic disorders. South. Med. J. (1988) 81:1103–1104.
  • MERIKANGAS JR, MERIKANGAS KR, KOPP U, HANIN I: Blood choline and response to clonazepam and haloperidol in Tourette's syndrome. Acta. Psychiatr. Scand. (1985) 72(4):395–399.
  • BLACK KJ, MINK PI: Response to levodopa challenge in Tourette syndrome. Mov. Disord. (2000) 15(6):1194–1198.
  • KURLAN R, MAJUMDAR L, DEELEY C, MUDHOLKAR GS, PLUMB S, COMO PG: A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome. Ann. Neurol. (1991) 30(1):19–23.
  • HERMAN BH, HAMMOCK MK, ARTHUR-SMITH A et al.: Naltrexone decreases self-injurious behavior. Ann. Neurol (1987) 22(4):550–552.
  • SANDYK R: Self-mutilation in Tourette's syndrome./ Child. Neurol (1988) 3(2):147–148.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.